State first MR-Linac: GenesisCare launches NSW-first adaptive radiation therapy technology for patients with prostate and oligometastatic cancer

Pinterest LinkedIn Tumblr +

GenesisCare at St Vincent’s Hospital in Darlinghurst has become the first oncology service in NSW and second in Australia to treat patients with a state-of-the-art Elekta Unity MR-Linac, available for patients with prostate or oligometastatic cancer.

The MR-Linac technology combines a high-field magnetic resonance imaging (MRI) scanner with a linear accelerator. This bolsters adaptive planning capabilities with simultaneous radiation delivery and real-time visualisation of high resolution anatomical and biological MR images.1-4

According to GenesisCare’s MR-Linac Lead Radiation Oncologist, Dr Jeremy de Leon, adaptive planning signals a major advance in radiation therapy, which aims to improve patient outcomes.

“MR-Linac technology allows radiation treatment plans to be tailored in response to changes in tumour position, shape and biology, all while the patient is on the treatment bed.1,2,4

“Visualising the tumour and surrounding tissue and organs in real time allows for more precise dose delivery. This reduces exposure to healthy tissue and enables improved dose escalation and fractionation not feasible with other systems.”

Many solid tumours, such as those of the prostate, shift during or between treatment sessions, or are located near critical organs or tissue, making them difficult to target with radiation. Precise, real-time imaging is therefore useful in determining exact boundaries and location for effective treatment.2,6,10

“This highly personalised and adaptive care may result in reduced treatment-related side effects and less treatment sessions with fewer visits to the hospital, thereby reducing the overall burden on patients,” said Dr de Leon.2,4

For approximately 50 per cent of all cancer patients, radiation therapy plays an important role in the treatment pathway, either for pain and symptom management or with curative intent.9

GenesisCare Chief Executive Officer, Dan Collins, said: “More than ever in these challenging times, we want to ensure that cancer patients around Australia and the world receive the right care when it’s needed. This is why we are continuing our investment in the latest technology through our partnership with Elekta.

“The Elekta Unity is a significant step forward for patients with complex cancers. Our goal to increase access to this innovative technology starts at St Vincent’s in Sydney and will extend through our international network, which includes more than 400 cancer treatment centres in Europe and now the USA. Our wonderful physicians and team members across GenesisCare are passionate innovators, and this system will allow them to realise outcomes for patients beyond what’s been possible before.

“We will also foster new research, techniques and innovation based around the huge potential of MR-guided radiation therapy,” said Mr Collins.

The Elekta Unity MR-Linac at GenesisCare St Vincent’s is now available to treat patients with prostate cancer or oligometastatic cancer.

Highly targeted and minimally invasive metastases-directed treatment, such as delivered using an MR-Linac, may enable clinicians to balance effective treatment with patient quality of life.2,5,6

Elekta Acting President and Chief Financial Officer, Gustaf Salford, said: “With a shared focus on patient centric care, we are uniting with GenesisCare to ensure treating clinicians can access the latest innovations in adaptive radiation therapy technology for their patients.”

A 63-year-old Sydney patient with prostate cancer is the first NSW patient treated with the Unity MR-Linac in July 2020.

Source: GenesisCare via VIVA Communications


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.